Keymed Biosciences Inc. Stock
Stocks
2162
KYG5252B1023
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.45 HKD | -3.63% |
|
+19.41% | +31.81% |
| 06-05 | Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close | MT |
| 06-04 | Lakefront Biotherapeutics, Gilead Complete Ouro Acquisition for $1.68 Billion Upfront | MT |
| Market Cap | 18.67B 21.54B 2.75B 2.4B 2.22B 2.07B 3.9B 260B 3.99B 26.71B 10.31B 128B 10.31B 10.09B 445B | P/E 2026 * |
36.6x | P/E 2027 * | 172x |
|---|---|---|---|---|---|
| Enterprise Value | 17.86B 20.61B 2.63B 2.3B 2.12B 1.98B 3.73B 248B 3.82B 25.56B 9.87B 123B 9.87B 9.65B 425B | EV / Sales 2026 * |
7.43x | EV / Sales 2027 * | 8.09x |
| Free-Float |
70.26% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -3.63% | ||
| 1 week | +19.41% | ||
| Current month | +14.00% | ||
| 1 month | +16.16% | ||
| 3 months | +17.12% | ||
| 6 months | +31.93% | ||
| Current year | +31.81% |
| 1 week | 59.15 |  | 74.25 |
| 1 month | 52.6 | | 74.25 |
| Current year | 44.66 | | 81.85 |
| 1 year | 44.45 | | 81.85 |
| 3 years | 26.6 | | 81.85 |
| 5 years | 16.9 | | 82.85 |
| 10 years | 16.9 | | 82.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bo Chen
CEO | Chief Executive Officer | 52 | 2018-04-22 |
Changyu Wang
PRN | Corporate Officer/Principal | 61 | 2021-03-02 |
Pak Yu Tam
SEC | Corporate Secretary | - | 2022-03-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Bo Chen
CHM | Chairman | 52 | 2018-04-22 |
Changyu Wang
BRD | Director/Board Member | 61 | 2021-03-02 |
Gang Xu
BRD | Director/Board Member | 52 | 2018-06-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25-06-12 | Moonshot Holdings Ltd.
| Other | Company | 21,600,000 | 7.7216% | |
| 25-06-10 | Moonshot Holdings Ltd.
| Other | Company | 18,800,000 | 6.7206% | |
| 23-09-14 | Moonshot Holdings Ltd.
| Other | Company | 114,500 | 0.0409% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.63% | +19.41% | +52.49% | +72.25% | 2.41B | |
| +0.13% | -1.33% | +63.86% | +121.93% | 55.63B | |
| +6.76% | +18.10% | +91.66% | +104.09% | 52.25B | |
| +3.33% | +4.51% | -11.68% | -11.91% | 23.07B | |
| +1.32% | +6.22% | +5.28% | +415.45% | 22.41B | |
| +0.97% | +3.81% | +31.23% | -32.21% | 15.94B | |
| -0.89% | +5.71% | +24.30% | +186.29% | 13.77B | |
| +9.96% | +15.98% | +157.65% | +310.89% | 13.47B | |
| +2.85% | +2.81% | +75.32% | +139.44% | 11.82B | |
| +6.17% | +10.22% | +163.15% | +166.44% | 11.16B | |
| Average | +2.70% | +9.55% | +65.33% | +147.27% | 22.19B | |
| Weighted average by Cap. | +3.15% | +7.74% | +63.01% | +140.47% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.41B 2.78B 354M 310M 286M 267M 503M 33.45B 514M 3.44B 1.33B 16.5B 1.33B 1.3B 57.3B | 2.16B 2.49B 317M 278M 256M 239M 451M 29.98B 461M 3.08B 1.19B 14.79B 1.19B 1.16B 51.35B |
| Net income | 295M 341M 43.47M 38.06M 35.14M 32.81M 61.76M 4.11B 63.17M 423M 163M 2.03B 163M 160M 7.04B | 44.14M 50.92M 6.49M 5.69M 5.25M 4.9M 9.23M 614M 9.44M 63.16M 24.38M 303M 24.38M 23.85M 1.05B |
| Net Debt | -804M -928M -118M -104M -95.65M -89.32M -168M -11.19B -172M -1.15B -444M -5.52B -444M -435M -19.16B | -1.23B -1.42B -181M -158M -146M -136M -257M -17.09B -263M -1.76B -679M -8.43B -679M -664M -29.28B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-29 | HK$70.45 | -3.63% | 2,211,914 |
| 26-06-29 | HK$73.10 | +14.13% | 5,813,974 |
| 26-06-26 | HK$64.05 | +1.91% | 3,626,008 |
| 26-06-25 | HK$62.85 | +3.03% | 4,836,828 |
| 26-06-24 | HK$61.00 | +3.39% | 3,956,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2162 Stock
Select your edition
All financial news and data tailored to specific country editions
